Title:
TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/138676
Kind Code:
A1
Abstract:
Disclosed in the present invention are a tricyclic fused heterocyclic compound having PDE3/4 dual inhibitory effect as represented by formula (I), and a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating/preventing PDE3/4-mediated diseases, wherein each group in formula (I) is as defined in the description.
Inventors:
LI YAO (CN)
ZHANG GUOBIAO (CN)
ZHANG XIAOBO (CN)
ZHANG YAMING (CN)
HUANG SHILIN (CN)
YAN LINJIE (CN)
TANG PINGMING (CN)
YU YAN (CN)
ZHANG CHEN (CN)
YAN PANGKE (CN)
ZHANG GUOBIAO (CN)
ZHANG XIAOBO (CN)
ZHANG YAMING (CN)
HUANG SHILIN (CN)
YAN LINJIE (CN)
TANG PINGMING (CN)
YU YAN (CN)
ZHANG CHEN (CN)
YAN PANGKE (CN)
Application Number:
PCT/CN2023/073288
Publication Date:
July 27, 2023
Filing Date:
January 20, 2023
Export Citation:
Assignee:
SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D471/04; A61K31/517; A61K31/519; A61P11/08
Domestic Patent References:
| WO2021143843A1 | 2021-07-22 | |||
| WO2020011254A1 | 2020-01-16 | |||
| WO2021143841A1 | 2021-07-22 |
Foreign References:
| CN1348453A | 2002-05-08 | |||
| CN101321758A | 2008-12-10 |
Attorney, Agent or Firm:
WU , FENG & ZHANG (CN)
Download PDF:
Previous Patent: QUINOLINE COMPOUND AND USE THEREOF
Next Patent: NOVEL ANTI-LAG3 ANTIBODIES AND DERIVATIVE PRODUCTS
Next Patent: NOVEL ANTI-LAG3 ANTIBODIES AND DERIVATIVE PRODUCTS